Reference

Protective effect of coenzyme Q on adriamycin toxicity in beating heart cells

Protective effect of coenzyme Q on adriamycin toxicity in beating heart cells. Kishi, Takeo; Takahashi, Kyoko; Mayumi, Tadanori; Hama, Takao (Fac. Pharm. Sci., Kobe-Gakuin Univ., Kobe 673, Japan). Biomed. Clin. Aspects Coenzyme Q, 4, 181-94 (English) 1984. CODEN: BCAQDA. ISSN: 0167-8450. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 18 Inhibition by adriamycin (ADM) [23214-92-8] of the beating of cultured mouse heart cells was dose- and time-dependent. A 50% cessation of beating was obsd. with doses of 430-520 mM ADM for 0.5 h, 70-100 mM ADM for 4 h, or 3.5 mM ADM for 36 h. When cultured heart cells were incubated with 3.5 mM [3H]ADM, the isotope was found to have been fully incorporated into the cells by 24 h, but the beating cell count continued to decrease gradually from 80% at 24 h to 10% at 72 h. The lipid peroxide level in the cells in the presence of 3.5 mM ADM had not significantly increased by 24 h, but had increased to about 1.5 times the control level, by 48 h. Addn. of 120 mM a-tocopherol (Toc) [59-02-9] in advance of the ADM treatment, depressed lipid peroxidn. by 86%, but did not protect beating from ADM toxicity. In contrast, 120 mM coenzyme Q10 (CoQ10) [303-98-0] reduced the lipid peroxidn. only by 33%, but increased the beating count at 48 h from 42% to 68%. Further, CoQ10 did not affect uptake of ADM by the cells. ADM inhibition of O uptake by the cells, was strongly correlated with percent cessation of beating, in the dosage range of 70-520 mM ADM. The ATP content of the cells in the presence of 3.5 mM ADM decreased following decrease in the beating cell count. Apparently stimulation of lipid peroxidn. by ADM does not initiate beat inhibition of the cultured heart cells; the protective effect of CoQ10 seems to be based on biochem. actions other than redn. of lipid peroxidn. and inhibition of ADM uptake.

Anthralin compositions for treating psoriasis

Anthralin compositions for treating psoriasis. Stiefel, W. K.; Nicolai, D. W. (Stiefel Laboratories, Inc., USA). Belg. BE 899975 A1 15 Oct 1984, 17 pp. (French). (Belgium). CODEN: BEXXAL. ICI: A61. APPLICATION: BE 21-186 20 Jun 1984. PRIORITY: US 83-506414 21 Jun 1983; US 84-585515 2 Mar 1984. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Topical compns. for psoriasis treatment consist of anthralin (I) [1143-38-0] 0.05-5%, a lipid-sol. antioxidant 0.02-2%, an emulsion contg. water and a liq. hydrocarbon in a ratio of 5:1 and 1 or more water-sol. substances such as carboxylic acids and a bifunctional sesquestering agent 0.02-2%. A topical compn. was prepd. by using the following ingredients: an oily phase contained mineral oil 6.0, paraffin 2.3, petrolatum 2.3, Al stearate 0.7, glyceryl oleate 1.5, anthralin 0.22, ascorbyl palmitate [137-66-6] 0.02, 2-octyldodecanol 3.0 and salicylic acid [69-72-7] 0.4%; an aq. phase contained water 68.82, citric acid [77-92-9] 0.9, di-Na EDTA [139-33-3] 0.06, sorbitol 13.5, Me p-hydroxybenzoate 0.15, Pr p-hydroxybenzoate 0.10 and a-tocopherol [59-02-9] 0.03%. The 2 phases were homogenized to form the emulsion.